Page 1,337«..1020..1,3361,3371,3381,339..1,3501,360..»

Troy resident ‘gets it done’ with ground-breaking treatment – Troy Daily News

Posted: September 26, 2019 at 8:45 am

For Miami Valley Today

TROY Bill Willoughby has always been an optimist. This positive approach to life would serve him well after being diagnosed with non-Hodgkins lymphoma in 2015.

I was going to a doctor and at one point he said with my condition, the best he could do was try to keep me in remission, explained Bill, a Troy resident. So, he referred me to Dr. Faber at OHC for a stem cell transplant. Being an optimist, I agreed and said, Im all in. Lets get it done.

Bill went to OHC for his chemotherapy followed by the stem cell transplant for his lymphoma. OHCs stem cell transplant experts have performed more than 2300 transplants since 1989.

Stem cell transplant is a life-saving option for many people with blood cancers, explained Edward Faber, Jr., MD, MS, an OHC medical oncologist, hematologist and transplant specialist. But for Bill, months later he relapsed and the cancer was in his lungs, liver and in his bones. Weve had excellent success with stem cell transplants. Unfortunately, there are some patients for whom it just doesnt work. Our entire team was sad to learn that Bill was one of those patients.

With the cancer now in his bones, Bill was experiencing more pain than before not good for someone who still hasnt retired from the building and rental property business. So, when Dr. Faber suggested another treatment option, Bill was again optimistic.

Bill was an ideal candidate for a relatively new treatment called chimeric antigen receptor T cell immunotherapy, or CAR-T, said Dr. Faber. This is a ground-breaking treatment that has demonstrated incredible outcomes in some patients for whom all hope was lost. OHC has been using CAR-T for almost a year now and were seeing positive results. Were hopeful this will be the case for Mr. Willoughby.

CAR-T is still relatively new for treating cancers. In fact, OHC is the only adult cancer practice in the region to offer CAR-T to adults with blood cancers. With CAR-T, doctors remove immune system cells from a patient, modify them in a lab so they will recognize and kill cancer cells, then infuse them back into the patient through an IV. The cells that are injected back into the patient stay in the body, becoming what some researchers refer to as living drugs in that they are ready to attack if that same cancer returns.

I had never heard of CAR-T when Dr. Faber told me about it, Bill said. He explained that it helps your immune system cells fight the cancer. So, I looked it up, especially because I was running out of options, and it seemed like a wonderful theory. They said Im the fourth OHC patient to get this treatment.

After completing his research and weighing his options, once again, Bills response was, Im all in. Lets get this done. Bill received his CAR-T treatment in July and today hes feeling good.

I had my last scan a few weeks ago and they said the cancer in my lungs is gone, the cancer in my liver has decreased, and I still have some spots in my bones but they too have decreased, Bill said. Ive started back to work. Ive been passionate about building and construction since I was 15 years old. Now Im 70 and Im still into it, although I mostly subcontract the work. But I have rental properties and still do that maintenance work.

CAR-T has demonstrated success like no other treatment before. It received breakthrough therapy designation from the Food and Drug Administration, which means the process for approval is moved along more quickly after initial clinical trials show strong results. The procedure is currently performed in a designated center, originally as a hospital inpatient procedure that is now being administered in a hospital outpatient department.

OHC is launching new clinical trials to determine if it can be given in a doctors office treatment suite setting, like OHC, said Dr. Faber. And soon, we hope to introduce clinical trials that will look to expand CAR-T to treat other cancers, like solid tumors.

We still have a way to go with CAR-T and other immunotherapies, but if its successful, it will forever change the way the world treats cancer. Its a whole new frontier for medicine, Dr. Faber added.

Ive always been an optimist and a Christian, and I look at this as a great thing thats happened to me, Bill added. So does my family. Ive already recommended it to a couple people I know whove also run out of options. I tell them to call Dr. Faber and see if he can get it for them. When your chances become limited and then you learn about this, you start to see a possible light at the end of the tunnel.

OHC is the only adult cancer group in the region to offer this advanced treatment to adults. For more information including an educational video, visit https://www.ohcare.com/service/car-t-cell-therapy/ or call (888) 649-4800.

Provided photo Pictured is OHC patient Bill Willoughby back at work thanks to CAR T-cell immunotherapy.

Willoughby undergoes stem cell transplant

View original post here:
Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News

Posted in Stem Cell Therapy | Comments Off on Troy resident ‘gets it done’ with ground-breaking treatment – Troy Daily News

Rheumatoid Arthritis Stem Cell Therapy Market to Witness Growth Acceleration During 2018 to 2028 – Analytics News

Posted: September 26, 2019 at 8:45 am

Rheumatoid arthritis stem cell therapy has been demonstrated to induce profound healing activity, halt arthritic conditions, and in many cases, reverse and regenerate joint tissue. Today, bone marrow transplant, adipose or fat-derived stem cells, and allogeneic mesenchymal stem cells (human umbilical cord tissue) are used for rheumatoid arthritis stem cell therapy. As the rheumatoid arthritis worsens, the body initiates autoimmune response and attacks the cells. Rheumatoid arthritis stem cell therapy is growing in popularity across hospitals, ambulatory surgical centers, and specialty clinics, as it increases the healing of joints and further treats the entire system that causes the joint pain and inflammation.

The stem cells with ability to stimulate regeneration, immune modulating capacity, and excellent anti-inflammatory activity can be screened and selected. In addition, abundant amount of mesenchymal stem cells can be obtained from umbilical cord tissue. These are some of the key factors favoring the development of rheumatoid arthritis stem cell therapy market. Government are heavily investing in healthcare sectors which is turn is expected to fuel growth of the rheumatoid arthritis stem cell therapy market. Growing research to find effective treatment for various autoimmune disorders will possibly create potential growth prospects of rheumatoid arthritis stem cell therapy market.

Rheumatoid arthritis is one of the many types of arthritis and is an autoimmune disorder. In patients with rheumatoid arthritis, the immune system attacks different parts of joints by generating cellular responses and antibodies to various tissues, including collagen, which leads to joint deterioration along with complications such as heart damage and pulmonary fibrosis. Rheumatoid arthritis affects 1% of the general population worldwide. Unfortunately, the available treatments cause adverse effects as they inhibit responses of the immune system in non-specific ways. Rheumatoid arthritis stem cell therapy is an alternative option as the therapy works to induce healing while regenerating healthy tissue. Rheumatoid arthritis stem cell therapy also has a modulating effect on the immune system, which helps in fighting diseases while turning off some of the pathological responses. Today, new treatments and advances in rheumatoid arthritis research are being studied. Rheumatoid arthritis stem cell therapy is being studied for its efficacy in improving complications in patients through the use of their own stem cells. These stem cell therapies may help patients who do not respond to typical drug treatment and want to reduce their reliance on medications or who are looking to try stem cell therapy before starting a drug treatment.

Request Sample Report-https://www.factmr.com/connectus/sample?flag=S&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market: Drivers and Restraints

The growing prevalence and recurrence of rheumatoid arthritis is expected to be the major factor driving the growth of the rheumatoid arthritis stem cell therapy market over the forecast period. Although doctors do not know the exact cause of rheumatoid arthritis, but certain risk factors are observed to be associated with it. These risk factors include age (most common between the age of 40 and 60), family history, gender, environment (a toxic chemical in the environment can up the odds), obesity and smoking. Changes in lifestyle and eating habits are contributing to the growing prevalence of rheumatoid arthritis. Development and addition of new therapies is the other factor contributing to the growth of the global rheumatoid arthritis stem cell therapy market. For instance, Belgian company TiGenix announced a randomized phase II trial of its adipose derived stem cell product Cx611. The trial started in 2015 for patients who have active rheumatoid arthritis despite being treated with methotrexate and steroids.

Rheumatoid Arthritis Stem Cell Therapy Market: Segmentation

Tentatively, the global rheumatoid arthritis stem cell therapy market can be segmented on the basis of treatment type, application, end user and geography.

Based on treatment type, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on application, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on distribution channel, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Based on geography, the global rheumatoid arthritis stem cell therapy market can be segmented into:

Have Any Query? Ask our Industry Experts-https://www.factmr.com/connectus/sample?flag=AE&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market: Overview

The global market for rheumatoid arthritis therapeutics is expected to witness moderate growth over the forecast period. Among the two treatment types, the allogeneic mesenchymal stem cell segment is expected to lead in the global rheumatoid arthritis stem cell therapy market over the forecast period. Hospitals are expected to contribute a considerable high share in the global rheumatoid arthritis stem cell therapy market as they are the most accessible channel.

Request/View [emailprotected]https://www.factmr.com/connectus/sample?flag=T&rep_id=1001

Rheumatoid Arthritis Stem Cell Therapy Market: Regional Outlook

Geographically, the global rheumatoid arthritis stem cell therapy market can be segmented into viz. North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East and Africa (MEA). North America is expected to be the dominant region in the global rheumatoid arthritis stem cell therapy market, owing to the presence of various key players. The rheumatoid arthritis stem cell therapy market in Asia Pacific excluding Japan is expected to grow at a significant CAGR due to the expansion of product offerings by key players. Europe is expected to have the second large share in the global rheumatoid arthritis stem cell therapy market throughout the forecast period.

Rheumatoid Arthritis Stem Cell Therapy Market: Key Players

The global market for rheumatoid arthritis stem cell therapy is highly fragmented. Examples of some of the key players operating in the global rheumatoid arthritis stem cell therapy market include Mesoblast Ltd., Roslin Cells, Regeneus Ltd, ReNeuron Group plc, International Stem Cell Corporation, TiGenix and others.

Report [emailprotected]https://www.factmr.com/report/1001/rheumatoid-arthritis-stem-cell-therapy-market

Here is the original post:
Rheumatoid Arthritis Stem Cell Therapy Market to Witness Growth Acceleration During 2018 to 2028 - Analytics News

Posted in Stem Cell Therapy | Comments Off on Rheumatoid Arthritis Stem Cell Therapy Market to Witness Growth Acceleration During 2018 to 2028 – Analytics News

God of miniscule things – Pune Mirror

Posted: September 26, 2019 at 8:45 am

Chug some fine brews as you soak up the science behind gene editingStem cells, which have the unique ability to morph into different types of cells, fascinate Dr Deepa Subramanyam, a researcher at the National Centre for Cell Science (NCCS) in the city. She has been studying stem cells for well over a decade, and has given talks on the subject. I have always been fascinated by how a handful of embryonic stem cells can create a perfectly patterned organism, says Subramanyam.

This weekend, Subramanyam has been invited as Science on Taps guest speaker. The scientists presentation is titled Godplayer stem cells, gene editing and playing god! Science on Tap was started as a talk series to connect the public with some of the countrys finest scientists in an informal setting. Anybody is welcome to attend the event regardless of their age and background. I avoid using scientific jargon to make my presentation accessible to the general public, she adds.

Subramanyam says that research on stem cells began about 30 years ago. She is certain that stem-cell therapy can treat most human ailments, such as diabetes and heart disease, in the near future. According to Subramanyam, trials are underway to determine the effectiveness of stem-cell therapy. She, however, cautions: I would say that one has to be careful about stem-cell therapy at the moment you should not undertake it without proper approval.

Subramanyam enjoys interacting with the public. In the past, she has addressed an audience comprising children, as part of an outreach programme. The talk was on stem cells. The scientist is always surprised by the intelligent questions that children ask her. Youngsters can come up with some of the most difficult questions, as they have access to a lot of information, says Subramanyam, who confesses that at times she has wondered how she should proceed to answer them.

WHERE: Mr Rabbits Bar & Burrow, Baner Road WHEN: September 28, 5 pm

Read the original here:
God of miniscule things - Pune Mirror

Posted in Stem Cell Therapy | Comments Off on God of miniscule things – Pune Mirror

Global Animal Stem Cell Therapy Market Regulations and Competitive Landscape Outlook, 2019 to 2026 – NY Tribunal 24

Posted: September 26, 2019 at 8:45 am

Global Animal Stem Cell Therapy Market Status and Forecast 2019-2026 delivers feasible and functional intelligence of the market that has been accurately analyzed using different models. The report contains significant information and factors influencing the industrial expansion of the global Animal Stem Cell Therapy market. The report considers the customer purchasing patterns, development rate, macroeconomic parameters, market demand, and supply states during the study of the geographical region. The detailed information regarding segments by type, application, regions, and manufacturers/players helps you monitor future productivity and make crucial decisions for future expansion.

Further, the report analyzes the market competition landscape using a SWOT analysis. In addition to this, it covers industry structure, market characteristics, problems, desire concepts, market effectiveness, and business strategies. The report focuses on an assessment of the impact of current market trends and conditions to provide information on the future market expansion.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/132383/request-sample

Scope of TheAnimal Stem Cell TherapyMarketReport: Geographically, the market is split into various key Regions including Asia-Pacific (China, Southeast Asia, India, Japan, Korea, Western Asia), Europe (Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland), North America (United States, Canada, Mexico), Middle East & Africa (GCC, North Africa, South Africa), South America (Brazil, Argentina, Columbia, Chile, Peru) on the basis of revenue (million USD), growth rate, market share (%), production, and consumption from 2019 to 2024 (forecast).

Global Animal Stem Cell Therapy market: manufacturers segment analysis (companies and product introduction, sales volume, revenue, price, and gross margin): MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics,

The market research study focuses on these types with production, revenue, price, market share, and growth rate of each type: Dogs, Horses, Others,

The market research study focuses on these applications with consumption, market share, and growth rate of each application: Veterinary Hospitals, Research Organizations,

Report Objective:

Various attributes of the market including growth and restraining factors, new opportunities, technological advancements, challenges, and emerging segments of the industry are further covered in this report. Company profiling with accurate methodologies, financial, and current improvements is another important section of this report. Tracking and scrutinizing the Animal Stem Cell Therapy market expansion, new product launches mergers, partnerships, agreement, collaborations, and acquisitions as well as research programs, development activities are some of the key purposes of the report.

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-animal-stem-cell-therapy-market-status-and-132383.html

Vital highlights of the Global Animal Stem Cell Therapy Market Report 2019 are:

Apart from the aforementioned information, trade and distribution analysis for theAnimal Stem Cell Therapy market, the contact information of major manufacturers, suppliers and key consumers is also included. Its a special combination of pivotal parameters such as competitive insights, business space, and the industry chain analysis. Further, it highlights the constituents affecting market growth, production, consumption, supply, import, export, cost, and gross margin.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs.

View post:
Global Animal Stem Cell Therapy Market Regulations and Competitive Landscape Outlook, 2019 to 2026 - NY Tribunal 24

Posted in Stem Cell Therapy | Comments Off on Global Animal Stem Cell Therapy Market Regulations and Competitive Landscape Outlook, 2019 to 2026 – NY Tribunal 24

Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications – Fabry Disease News

Posted: September 26, 2019 at 8:45 am

Heart cells derived from patients stem cells and grown in a lab dish can reveal important clues about the development of heart ailments associated with Fabry disease.

The study, A Human Stem Cell Model of Fabry Disease Implicates LIMP-2 Accumulation in Cardiomyocyte Pathology, was published in Stem Cell Reports.

Fabry is a rare genetic disorder caused by mutations in the GLA gene. Located on the X chromosome, the gene provides instructions for the production of an enzyme called alpha-galactosidase A (alpha-GAL A).

These mutations typically affect the activity of alpha-GAL A, leading to the accumulation of a type of fat called globotriaosylceramide (GL-3) in different tissues and organs, including the heart, kidneys and nervous system, gradually compromising their normal function.

For this reason, most Fabry patients develop heart disease over the course of their lives, which may progress to heart failure, the most common cause of death among people living with the disorder.

A major obstacle for advancing therapy for patients with [Fabry disease] is the knowledge gap between the direct molecular consequences of alpha-GAL A deficiency in CMs [cardiomyocytes, or heart cells] and the cascade of events driving disease in the heart; the inaccessibility of CMs from patients precludes adequate investigation of these events, especially at early stages, the investigators wrote.

In a previous study, researchers describe the generation of induced pluripotent stem cells (iPSCs) from Fabry patients carrying nonsense mutations in the GLA gene. This gave them the possibility, for the first time, to study the impact of alpha-GAL A deficiency on heart cells derived from patients iPSCs grown in a lab dish.

(iPSCs are fully matured cells that are reprogrammed back to a stem cell state, where they are able to grow into any type of cell. A nonsense mutation is a mutation in which the alteration of a single nucleotide (the building blocks of DNA) makes proteins shorter.)

Investigators from Sanofi, in collaboration with researchers at the University of Manchester, further investigated the properties of heart cells derived from patients iPSCs. Their aim was to discover more clues about the molecular mechanisms involved in the development of heart disease linked to Fabry.

Functional and structural characterization experiments revealed that heart cells from Fabry patients had higher levels of GL-3, and showed a series of abnormalities in the way they responded to electrical stimuli and in how they regulated their calcium usage, compared to heart cells from healthy people serving as controls. Calcium is essential to coordinate the hearts function by contributing to the electrical signals involved in heart muscle contraction.

When researchers analyzed the protein contents of heart cells grown in a lab dish, they found these cells produced more than 5,500 different proteins. This analysis also showed that compared to controls, heart cells from Fabry patients produced large amounts of lysosomal membrane protein 2 (LIMP-2) and heat shock-related 70 kDa protein 2 (HSPA2/HSP70-2).

(LIMP-2 is a protein normally found on the membrane of lysosomes small structures within cells that accumulate, digest, and recycle materials that regulates their transport within cells; HSPA2/HSP70-2 is a protein involved in cellular quality control, participating in the folding of other proteins and targeting abnormal proteins for degradation.)

Heart cells from Fabry patients released high amounts of cathepsin F, a protein that helps breakdown materials being transported inside lysosomes, as well as HSPA2/HSP70-2. As expected, when researchers corrected the genetic mutation associated with Fabry in heart cells derived from patients iPSCs, all these defects were reversed.

To confirm the validity of these proteins as Fabry biomarkers, researchers then forced healthy heart cells to produce high amounts of LIMP-2. They discovered this also triggered the release of large amounts of cathepsin F and HSPA2/HSP70-2, resulting in a massive accumulation of vacuoles (enclosed compartments filled with water and other substances) inside cells.

In summary, our study has shown the power of the iPSC model to reveal early functional changes and the development of a distinctive biomarker expression profile in [Fabry disease] CMs. These biomarkers may be of utility in drug screening and in elucidating the earliest pathological events and cascades in [Fabry disease] cells. Quantification in patient plasma and urine samples will be an important next step toward validating their relevance in patients, the researchers wrote.

A better understanding of these mechanisms will no doubt accelerate the development of more effective and increasingly personalized therapies for patients, they added.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that make up the lining of blood vessels found in the umbilical cord of newborns.

Read the rest here:
Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications - Fabry Disease News

Posted in Stem Cell Therapy | Comments Off on Fabry Heart Cells Grown in Lab Dish Give Hints to Cardiac Complications – Fabry Disease News

Global Cancer Stem Cell Therapy Market 2019 Competitive Landscape, Trends and Future Forecast by Region 2024 – ScoopJunction

Posted: September 26, 2019 at 8:45 am

posted on September 24, 2019

The report offers detailed coverage of Cancer Stem Cell Therapy industry and main market trends. The historical surveying incorporates authentic and estimate showcase information, request, application subtleties, price trends, and company shares of the leading Cancer Stem Cell Therapy by geography. The report parts the market size, by volume and worth, based on application type and topography.

Cancer Stem Cell Therapy is expected to expand rapidly in all development areas over the forecast period between 2020 and 2024. Cancer Stem Cell Therapy industry report focuses on the major drivers and present competition status with growth prospects. Cancer Stem Cell Therapy the business report is professional and in-depth research by experts on the current state of the Cancer Stem Cell Therapy Industry. Cancer Stem Cell Therapy industry research report provides the latest industry data and future trends, allowing you to identify the products and profitability.

Request For Sample : https://vertexmarketinsights.com/report/33703/global-cancer-stem-cell-therapy-market-status-2015-2019-and-forecast-2020-2024-by-region-product-type-end-use/#request-sample

Maket Segmentation By Key Players :

Major Players:

AVIVA BioSciencesAdnaGenAdvanced Cell DiagnosticsSilicon Biosystems

The report of global Cancer Stem Cell Therapy market includes the competitive scene area which gives the full and top to bottom investigation of the present market trends, changing technologies and developments that will it is advantageous for organizations that struggle in the market.

First, this report covers the present status and the future prospects of the global Cancer Stem Cell Therapy market for 2015-2024. And in this report, we analyze global Cancer Stem Cell Therapy market from 5 geographies: India, Japan, Korea, Western Asia], North Africa, South Africa], Europe[Germany, UK, Netherlands, Italy, Russia, Spain, Turkey, France, Switzerland], Middle East & Africa[GCC, South America[Brazil, Argentina, Columbia, Chile, Peru], North America[United States, Canada, Mexico], Asia-Pacific[China, Southeast Asia,.

Below Table contains Types & Applications of Cancer Stem Cell Therapy Report

If you have any Query Ask to Our Support Team @ https://vertexmarketinsights.com/report/33703/global-cancer-stem-cell-therapy-market-status-2015-2019-and-forecast-2020-2024-by-region-product-type-end-use/#inquiry-before-buying

Report Highlights:

Detailed overview of parent market Changing market dynamics of the industry Top to bottom market division Historical, current and anticipated market size regarding volume and Value Recent industry examples and upgrades Competitive scene Strategies of key players and item contributions Potential and specialty fragments/regions display promising development An unbiased point of view towards market performance Must-have information for market players to sustain and enhance their market footprints

What To Expect From This Report On Cancer Stem Cell Therapy Market?

1. A detailed overview of various regional distributions and the overview types of trendy products in the Cancer Stem Cell Therapy Market.

2. Detailed Estimate the break-in for new players who want to enter the Cancer Stem Cell Therapy Market.

3. You can fix up the developmental programs for your business when you have info on the value of the production, value of the products, cost of the production for the next future years.

4. Detailed research on the overall expansion within the Cancer Stem Cell Therapy Market that helps you choose the item dispatch and administration improvements.

5. How do the leading companies and mid-level companies make revenue within the Cancer Stem Cell Therapy Market?

Explore Detailed Report @: https://vertexmarketinsights.com/report/33703/global-cancer-stem-cell-therapy-market-status-2015-2019-and-forecast-2020-2024-by-region-product-type-end-use/#table-of-contents

Read the original here:
Global Cancer Stem Cell Therapy Market 2019 Competitive Landscape, Trends and Future Forecast by Region 2024 - ScoopJunction

Posted in Stem Cell Therapy | Comments Off on Global Cancer Stem Cell Therapy Market 2019 Competitive Landscape, Trends and Future Forecast by Region 2024 – ScoopJunction

LuxInbound: LigneSante on the Forefront of Integrative Medicine Collaboration – P&T Community

Posted: September 26, 2019 at 8:44 am

More visibility for the professional, more ease of access to the care network for the patients.

LAUSANNE, Switzerland, Sept. 25, 2019 /PRNewswire/ -- LigneSantetoday announced their collaboration approach to Integrative medicine. They focus on the practice of medicine that reaffirms the importance of the relationship between the patient and the healthcare professional. They are focused on the whole person, informed by evidence, and makes use of all appropriate therapeutic approaches, with health professionals and disciplines to achieve the best of health and healing.

"Integrative medicine proposes a partnership between the doctor and their patient." - Dr. M. Fumagalli, Founder

Integrative medicineproposes a partnership between the doctor and his patient for the maintenance of health. It starts by placing the patient as the main actor in the process, as his health agent. The patient no longer passively receives treatment for an illness and actively participates in their health. Health is also an individual responsibility.

In this partnership, integrative medicine brings together professionals from different areas because interdisciplinarity is essential to take care of a patient. It is associated with the treatment of conventional medicine making use of alternative medicineknowledge, such as meditative practices, breathing techniques, relaxation, mindfulness, use of herbal medicines, always based on evidence regarding safety and efficacy.

The service provided by therapists of integrative medicineconsists of non-invasive body techniques, free of any religious basis and adapted to the needs and limitations of the patient. Performed individually, they may include physical practices such as stretching, breathing exercises, light massages (without oils or cream) and relaxation practices conducted by the therapist's speech (voice).

The objective of the work is to provide moments of relaxation and well-being to reduce anxiety and stress, be it emotional, physical, or mental.

The basis of the work is the practice of mindfulness exercises in the present moment, which provides this state of well-beingand deep relaxation.

The basis of the work is the practice of mindfulness exercises in the present moment, which provides this state of well-being and deep relaxation.

This deep relaxation helps patients identify their needs and report symptoms to medical and care staff.

Stress management techniques are taught to patients and caregivers so that they routinely use them at all times during treatment.

Principles of Integrative Medicine:

LigneSantewill be available for a 90-day free trial. For more information visit https://lignesante.com/

About LigneSante: We are a community of medical professionals, sharing ideas, comparing notes, referring patients, and striving for an integrated approach of medicine. Ultimately for the betterment of humankind.

Jayson Lux Lux Inbound +41-78-664-76-71 jayson@luxinbound.com

Photo: https://mma.prnewswire.com/media/1001162/LigneSante_integrated_health.jpgLogo: https://mma.prnewswire.com/media/997556/LigneSante_Logo.jpg

The rest is here:
LuxInbound: LigneSante on the Forefront of Integrative Medicine Collaboration - P&T Community

Posted in Integrative Medicine | Comments Off on LuxInbound: LigneSante on the Forefront of Integrative Medicine Collaboration – P&T Community

At Nearly $335M, Giving to UA Foundation Breaks Record – UANews

Posted: September 26, 2019 at 8:43 am

For the second year in a row, alumni and friends broke the record for philanthropic support of the University of Arizona, giving $334.6 million to the UA Foundation during fiscal year 2019. The previous fiscal year, the total for gifts, pledges and realized bequests topped $300 million for the first time, coming in at $317 million.

"Breaking our fundraising record two years in a row is a testament to the generosity of the University of Arizona community," said UA President Robert C. Robbins. "Fulfilling our commitment to expand human potential, explore new horizons and enrich life for all will take Wildcats and supporters from all walks of life coming together to support our mission, and with this result we are showing the world what it means to Bear Down."

The UA was recognized during the past year as one of America's 100 favorite charities. The Chronicle of Philanthropy identified the organizations Americans are most willing to support, based on how much they raised in cash and stock. The UA was the only Arizona university to make the list.

The past two years were noteworthy not only for overall philanthropy but for endowment giving, said John-Paul Roczniak, who is vice president of development and chief development officer for the UA and president and CEO of the UA Foundation.

Gifts to endowed scholarships, faculty chairs, and program and research funds build the university's endowment. The university's goal is to bring the endowment to $1 billion by 2021 in order to strengthen its financial bedrock for the future and better serve humanity today, said Roczniak.

On June 30, which marked the end of the fiscal year, the UA endowment had reached $928 million, a 9.5% increase over the previous year-end total.

"I'm immensely grateful for what generosity is doing for this university," said Roczniak. "We're on track to reach our endowment goal, and we're well positioned to begin implementing our strategic plan, with student support as our first priority."

Investments in Students and Faculty

One of the year's major gifts came from an anonymous donor who gave a total of $25 million to the College of Engineering and the UA Cancer Center. The gift will provide substantial support to engineering students and faculty, said David Hahn, dean of the College of Engineering.

"This gift enables us to take a quantum step forward in making the UA the kind of a destination where students want to come because of the richness of our curriculum and the unique things that we're doing," he said.

Two more of this year's significant gifts were made by Dr. Andrew Weil and James Wyant, distinguished faculty members who invested in the future of scholarship at the UA through endowed chairs. Endowed chairs greatly increase the university's ability to retain and attract exceptional faculty members and provide the chair holders with resources to advance their research and teaching.

Weil, an integrative medicine pioneer, best-selling author and philanthropist, committed $15 million, adding to a previous $5 million gift. His new contribution named the Andrew Weil Center for Integrative Medicine and established the Andrew Weil Endowed Chair in Integrative Medicine, the Andrew Weil Endowed Chair for Research in Integrative Medicine and the Andrew Weil Endowed Program Fund for Integrative Medicine.

Dr. Victoria Maizes, the center's director since 2004, is the inaugural holder of the Andrew Weil Endowed Chair in Integrative Medicine. The first holder of the Andrew Weil Endowed Chair for Research in Integrative Medicine is Dr. Esther Sternberg, director of research for the Andrew Weil Center for Integrative Medicine since 2012.

Wyant's gift was the university's largest ever for endowed chair positions. Wyant and his family made a $20 million gift to empower the college to recruit faculty for a minimum of 10 endowed chairs.

Wyant is founding dean and professor emeritus of the James C. Wyant College of Optical Sciences and has co-founded two optics companies. He has been recognized as a pioneer in the optics and photonics field with numerous awards.

In 2013, Wyant gave $10 million for graduate student scholarships in a campaign called FoTO, an acronym for Friends of Tucson Optics. As a result, 30 scholarship endowments were established, each bearing the name of a donor. As with the FoTO campaign, the Wyant family's gift for endowed chairs offers matching funds to inspire others to give.

Both Weil's gift and the Wyant family's qualify for amplified funding through the state-funded Eminent Scholars Program. This means each donated fund will grow more quickly and provide more immediate support than is typical with an endowed chair.

Leading the Fundraising Effort

The UA was recognized for excellence in fundraising this past year with an Educational Fundraising Award from the Council for Advancement and Support of Education. The university's fundraising, endowment investing, and gift stewardship are managed by the UA Foundation, a nonprofit with a mission to advance the UA.

The UA Foundation's board members are volunteer business and civic leaders and university executives, including Robbins. Seven new members joined the board this year.

The UA Foundation's directors elect officers to lead the organization. Board officers for 2019-2020 are as follows.

"This is a thrilling and rewarding time to invest in the UA. I encourage community members, alumni, parents and students to volunteer, get involved in the university, and give if you can. It will benefit you and others," Hinderaker said.

Access the complete list of board members here.

Read more:
At Nearly $335M, Giving to UA Foundation Breaks Record - UANews

Posted in Integrative Medicine | Comments Off on At Nearly $335M, Giving to UA Foundation Breaks Record – UANews

UCI study reveals critical role of new brain circuits in improving learning and memory for Alzheimers disease treatment – Newswise

Posted: September 26, 2019 at 8:43 am

MEDIA CONTACT

Available for logged-in reporters only

Newswise Irvine, Calif. September 23, 2019 - A University of California, Irvine-led team of scientists has discovered how newly identified neural circuits in the brains hippocampal formation play a critical role in object-location learning and memory.

The study, published today in Nature Neuroscience, was led by Xiangmin Xu, PhD, an anatomy and neurobiology professor in the UCI School of Medicine, and conducted in collaboration with Douglas A. Nitz, PhD, professor and chair of the Department of Cognitive Science at the University of California, San Diego; Qing Nie, PhD, Chancellor's Professor of mathematics and developmental and cell biology at UCI; and, Todd C. Holmes, professor and vice chair of UCIs Department of Physiology & Biophysics.

Loss of object location memory is one of the key impairments in Alzheimers disease (AD), the most common form of dementia in the elderly. These new findings in hippocampal circuit mechanisms provide an intriguing new target to counteract AD-related memory impairments.

Our study was made possible by new viral genetic based mapping approaches for examining connectivity between structures. These new mapping tools enabled us to identify novel circuits within and between the hippocampus and cortex, said Xu.

Xu and his colleagues used monosynaptic rabies retrograde tracing and herpes (H129)-based anterograde tracing to establish new cortico-hippocampal circuitry associated with subiculum (SUB) projections to hippocampal CA1. Xu and an international team of investigators was recently awarded an NIH BRAIN Initiative grant to develop new H129 viral tracers as a brain mapping tool for use by the entire neuroscience community.

The team revealed the hippocampal sub-circuit mechanism highly relevant to learning and memory disorders including Alzheimer's disease. These findings may be used to better treat Alzheimers disease and other neurological disorders, delay their onset, and possibly prevent them from developing in the first place.

This study was supported by the National Institutes of Health, including a BRAIN Initiative grant and other grants, the National Science Foundation, and the Simons Foundation.

About the UCI School of Medicine: Each year, the UCI School of Medicine educates more than 400 medical students, as well as 200 doctoral and masters students. More than 600 residents and fellows are trained at UC Irvine Medical Center and affiliated institutions. The School of Medicine offers an MD; a dual MD/PhD medical scientist training program; and PhDs and masters degrees in anatomy and neurobiology, biomedical sciences, genetic counseling, epidemiology, environmental health sciences, pathology, pharmacology, physiology and biophysics, and translational sciences. Medical students also may pursue an MD/MBA, an MD/masters in public health, or an MD/masters degree through one of three mission-based programs: the Health Education to Advance Leaders in Integrative Medicine (HEAL-IM), the Leadership Education to Advance Diversity-African, Black and Caribbean (LEAD-ABC), and the Program in Medical Education for the Latino Community (PRIME-LC). The UCI School of Medicine is accredited by the Liaison Committee on Medical Accreditation and ranks among the top 50 nationwide for research. For more information, visit som.uci.edu.

###

SEE ORIGINAL STUDY

Continue reading here:
UCI study reveals critical role of new brain circuits in improving learning and memory for Alzheimers disease treatment - Newswise

Posted in Integrative Medicine | Comments Off on UCI study reveals critical role of new brain circuits in improving learning and memory for Alzheimers disease treatment – Newswise

Omega-3s Recommended as Adjunctive Therapy for Major Depression – Medscape

Posted: September 26, 2019 at 8:43 am

A clinical practice guideline from the International Society for Nutritional Psychiatry Research (ISNPR) recommends omega-3 polyunsaturated fatty acids (PUFAs) as adjunctive therapy for major depressive disorder (MDD).

The value of omega-3 PUFAs in depression is "overlooked," even though accumulating evidence supports it. This therapy "needs to be on the radar" of physicians, Kuan-Pin Su, MD, PhD, chief of the Department of General Psychiatry, China Medical University, Taichung, Taiwan, told Medscape Medical News.

Su, a founding member of the ISNPR and a strong proponent of "nutritional psychiatry," organized a subcommittee of the ISNPR and invited the top 10 most-cited authors in the use of omega-3 PUFAs for depression to review the literature and develop the practice guideline on appropriate prescribing of omega-3 fatty acids for MDD.

The consensus guideline was published online September 3 in Psychotherapy and Psychosomatics.

The guideline emphasizes the importance of accurate clinical diagnosis and measurement-based psychopathologic assessments in the therapeutic setting when recommending omega-3 PUFAs for depression.

The guideline notes that there is a growing body of evidence demonstrating the efficacy of n-3 PUFAs as an adjunctive treatment for MDD. The guideline authors also note that omega-3s are safe and effective for accelerating the effect of antidepressants at treatment initiation and for augmenting existing antidepressant therapy when efficacy is inadequate.

With respect to formulation and dosage, the guideline recommends pure eicosapentaenoic acid (EPA) or a combination of EPA and docosahexaenoic acid, with net EPA starting from at least 1 g/day up to 2 g/day for at least 8 weeks as adjunctive treatment. Importantly, the authors note that the quality of n-3 PUFAs may affect therapeutic activity.

The guideline also endorses n-3 PUFAs as a potential prophylactic treatment for high-risk populations, in addition to standard medical care. The duration of acute n-3 PUFA treatment may be extended to include maintenance treatment to prevent recurrence.

Potential side effects, such as gastrointestinal and dermatologic conditions, should be monitored, and comprehensive metabolic panels should be obtained during treatment, the guideline authors note.

They call for further research into personalizing the clinical application of n-3 PUFAs in subgroups of patients with MDD whose omega-3 index is low or who have high levels of inflammatory markers.

The panel acknowledges in the guideline that there is ongoing debate on the benefits of omega-3 PUFAs for MDD. Meta-analyses have shown "only small but statistically significant effects," the authors write.

They note that in three meta-analyses, the estimated effect sizes (standardized mean differences between n-3 PUFAs and placebo) ranged from 0.23 to 0.56, with wide confidence intervals (CIs).

However, small effect sizes have also been reported regarding antidepressant drugs compared to placebo (standardized mean differences, 0.30 0.47, with narrower CIs).

Given that currently recommended therapies for MDD have only small effects, the panel notes three "practical" strategies that should be employed to address the "unmet" need in depression treatment.

These include an open-minded attitude to integrative intervention; the application of personalized medicine; and a shared decision-making process based on balanced information to enhance treatment adherence.

Commenting for Medscape Medical News, Timothy Sullivan, MD, chair of psychiatry and behavioral sciences at Northwell Health's Staten Island University Hospital in New York City, said the recommendation constitutes a "perfectly reasonable practice guideline.

"The big picture, however, is that while there is a literature on the usefulness of omega-3s, average clinical experience hasn't been as impressive. Clinicians generally haven't been overwhelmed by the results. There are practitioners that favor them more than others," said Sullivan.

"Conceptually," he added, "what's appealing about omega-3s is we know that depressive states are associated with dysregulation of the immune system, and agents like the omega-3s appear to have a role in helping to re-regulate or positively regulate the immune system and combat some of the metabolic effects of stress. But it's still an area that we need to understand more about."

The guideline authors were supported by research grants from the Ministry of Science and Technology, Taiwan; the National Health Research Institutes, Taiwan; and the Chinese Medicine Research Center from the China Medical University. Su is a founding committee member of the ISNPR, the board director of the International Society for the Study of Fatty Acids, and an associate editor of Brain, Behavior and Immunity. The original article contains a complete list of authors' relevant financial relationships. Sullivan has disclosed no relevant financial relationships.

Psychother Psychosom. Published online September 3, 2019. Full text

For more Medscape Psychiatry news, join us on Facebook and Twitter

Excerpt from:
Omega-3s Recommended as Adjunctive Therapy for Major Depression - Medscape

Posted in Integrative Medicine | Comments Off on Omega-3s Recommended as Adjunctive Therapy for Major Depression – Medscape

Page 1,337«..1020..1,3361,3371,3381,339..1,3501,360..»